These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 38170429)

  • 1. Updated Response Assessment in Neuro-Oncology (RANO) for Gliomas.
    Youssef G; Wen PY
    Curr Neurol Neurosci Rep; 2024 Feb; 24(2):17-25. PubMed ID: 38170429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of Standard Response Assessment in Neuro-Oncology, Modified Response Assessment in Neuro-Oncology, and Immunotherapy Response Assessment in Neuro-Oncology in Newly Diagnosed and Recurrent Glioblastoma.
    Youssef G; Rahman R; Bay C; Wang W; Lim-Fat MJ; Arnaout O; Bi WL; Cagney DN; Chang YS; Cloughesy TF; DeSalvo M; Ellingson BM; Flood TF; Gerstner ER; Gonzalez Castro LN; Guenette JP; Kim AE; Lee EQ; McFaline-Figueroa JR; Potter CA; Reardon DA; Huang RY; Wen PY
    J Clin Oncol; 2023 Jun; 41(17):3160-3171. PubMed ID: 37027809
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults.
    Wen PY; van den Bent M; Youssef G; Cloughesy TF; Ellingson BM; Weller M; Galanis E; Barboriak DP; de Groot J; Gilbert MR; Huang R; Lassman AB; Mehta M; Molinaro AM; Preusser M; Rahman R; Shankar LK; Stupp R; Villanueva-Meyer JE; Wick W; Macdonald DR; Reardon DA; Vogelbaum MA; Chang SM
    J Clin Oncol; 2023 Nov; 41(33):5187-5199. PubMed ID: 37774317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response Assessment in Neuro-Oncology Criteria and Clinical Endpoints.
    Huang RY; Wen PY
    Magn Reson Imaging Clin N Am; 2016 Nov; 24(4):705-718. PubMed ID: 27742111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Application of novel response/progression measures for surgically delivered therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group.
    Vogelbaum MA; Jost S; Aghi MK; Heimberger AB; Sampson JH; Wen PY; Macdonald DR; Van den Bent MJ; Chang SM
    Neurosurgery; 2012 Jan; 70(1):234-43; discussion 243-4. PubMed ID: 21593697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response Assessment in Pediatric Neuro-Oncology: Implementation and Expansion of the RANO Criteria in a Randomized Phase II Trial of Pediatric Patients with Newly Diagnosed High-Grade Gliomas.
    Jaspan T; Morgan PS; Warmuth-Metz M; Sanchez Aliaga E; Warren D; Calmon R; Grill J; Hargrave D; Garcia J; Zahlmann G
    AJNR Am J Neuroradiol; 2016 Sep; 37(9):1581-7. PubMed ID: 27127006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response Assessment in Neuro-Oncology criteria, contrast enhancement and perfusion MRI for assessing progression in glioblastoma.
    Tensaouti F; Khalifa J; Lusque A; Plas B; Lotterie JA; Berry I; Laprie A; Cohen-Jonathan Moyal E; Lubrano V
    Neuroradiology; 2017 Oct; 59(10):1013-1020. PubMed ID: 28842741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Automated quantitative tumour response assessment of MRI in neuro-oncology with artificial neural networks: a multicentre, retrospective study.
    Kickingereder P; Isensee F; Tursunova I; Petersen J; Neuberger U; Bonekamp D; Brugnara G; Schell M; Kessler T; Foltyn M; Harting I; Sahm F; Prager M; Nowosielski M; Wick A; Nolden M; Radbruch A; Debus J; Schlemmer HP; Heiland S; Platten M; von Deimling A; van den Bent MJ; Gorlia T; Wick W; Bendszus M; Maier-Hein KH
    Lancet Oncol; 2019 May; 20(5):728-740. PubMed ID: 30952559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RANO 2.0 criteria: concepts applicable to the neuroradiologist's clinical practice.
    Sanvito F; Castellano A; Cloughesy TF; Wen PY; Ellingson BM
    Curr Opin Oncol; 2024 Nov; 36(6):536-544. PubMed ID: 39011735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Updated response assessment criteria for high-grade glioma: beyond the MacDonald criteria.
    Sharma M; Juthani RG; Vogelbaum MA
    Chin Clin Oncol; 2017 Aug; 6(4):37. PubMed ID: 28841799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pros and cons of current brain tumor imaging.
    Ellingson BM; Wen PY; van den Bent MJ; Cloughesy TF
    Neuro Oncol; 2014 Oct; 16 Suppl 7(Suppl 7):vii2-11. PubMed ID: 25313235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Refinement of response assessment in neuro-oncology (RANO) using non-enhancing lesion type and contrast enhancement evolution pattern in IDH wild-type glioblastomas.
    Moon HH; Kim HS; Park JE; Kim YH; Kim JH
    BMC Cancer; 2021 Jun; 21(1):654. PubMed ID: 34074252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Artificial intelligence (AI)-based decision support improves reproducibility of tumor response assessment in neuro-oncology: An international multi-reader study.
    Vollmuth P; Foltyn M; Huang RY; Galldiks N; Petersen J; Isensee F; van den Bent MJ; Barkhof F; Park JE; Park YW; Ahn SS; Brugnara G; Meredig H; Jain R; Smits M; Pope WB; Maier-Hein K; Weller M; Wen PY; Wick W; Bendszus M
    Neuro Oncol; 2023 Mar; 25(3):533-543. PubMed ID: 35917833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response assessment of bevacizumab in patients with recurrent malignant glioma using [18F]Fluoroethyl-L-tyrosine PET in comparison to MRI.
    Galldiks N; Rapp M; Stoffels G; Fink GR; Shah NJ; Coenen HH; Sabel M; Langen KJ
    Eur J Nucl Med Mol Imaging; 2013 Jan; 40(1):22-33. PubMed ID: 23053325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modified Criteria for Radiographic Response Assessment in Glioblastoma Clinical Trials.
    Ellingson BM; Wen PY; Cloughesy TF
    Neurotherapeutics; 2017 Apr; 14(2):307-320. PubMed ID: 28108885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Neuroradiologist's Guide to Operationalizing the Response Assessment in Neuro-Oncology (RANO) Criteria Version 2.0 for Gliomas in Adults.
    Ellingson BM; Sanvito F; Cloughesy TF; Huang RY; Villanueva-Meyer JE; Pope WB; Barboriak DP; Shankar LK; Smits M; Kaufmann TJ; Boxerman JL; Weller M; Galanis E; Groot J; Gilbert MR; Lassman AB; Shiroishi MS; Nabavizadeh A; Mehta M; Stupp R; Wick W; Reardon DA; Vogelbaum MA; van den Bent M; Chang SM; Wen PY
    AJNR Am J Neuroradiol; 2024 Sep; ():. PubMed ID: 38926092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Classification of High-Grade Glioma into Tumor and Nontumor Components Using Support Vector Machine.
    Blumenthal DT; Artzi M; Liberman G; Bokstein F; Aizenstein O; Ben Bashat D
    AJNR Am J Neuroradiol; 2017 May; 38(5):908-914. PubMed ID: 28385884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of 2D (RANO) and volumetric methods for assessment of recurrent glioblastoma treated with bevacizumab-a report from the BELOB trial.
    Gahrmann R; van den Bent M; van der Holt B; Vernhout RM; Taal W; Vos M; de Groot JC; Beerepoot LV; Buter J; Flach ZH; Hanse M; Jasperse B; Smits M
    Neuro Oncol; 2017 Jun; 19(6):853-861. PubMed ID: 28204639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.
    Wen PY; Macdonald DR; Reardon DA; Cloughesy TF; Sorensen AG; Galanis E; Degroot J; Wick W; Gilbert MR; Lassman AB; Tsien C; Mikkelsen T; Wong ET; Chamberlain MC; Stupp R; Lamborn KR; Vogelbaum MA; van den Bent MJ; Chang SM
    J Clin Oncol; 2010 Apr; 28(11):1963-72. PubMed ID: 20231676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response assessment in neuro-oncology.
    Quant EC; Wen PY
    Curr Oncol Rep; 2011 Feb; 13(1):50-6. PubMed ID: 21086192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.